Attovia reports 12-week data from ATTO-1310 itch therapy trial
Attovia Therapeutics (NASDAQ:ATTO) reported 12-week Phase 1b trial results for ATTO-1310, an anti-IL-31 therapy. In chronic pruritus patients, 82% of treated patients saw a 4-point reduction in itch versus 22% with placebo. In high-itch atopic dermatitis patients, 44% of treated patients achieved a 4-point reduction versus 75% with placebo. The drug was generally well-tolerated, with plans for Phase 2 trials in 2027.
How this was made
The 30-second read
Why it matters
The release of Phase 1b data provides the first quantitative efficacy readout, which can materially affect valuation and funding prospects.
Market read
First‑time trial data for a micro‑cap biotech often trigger significant price moves, making this a high‑impact news item.
What to watch
Potential safety signals and the need for substantial funding to advance to Phase 2 could temper upside.
Background
Attovia Therapeutics (NASDAQ:ATTO) is a clinical‑stage biotech focused on anti‑IL‑31 therapies for chronic itch conditions.
Ticker impact
Attovia Therapeutics released first‑time topline 12‑week Phase 1b data for ATTO‑1310, showing significant itch reduction and IL‑31 suppression.
likely upward pressure as the market prices in the promising trial data
The data are a primary disclosure, showing strong efficacy signals and a clear path to Phase 2, which is material for a micro‑cap biotech.
Market effects
May lift sentiment for other itch‑therapy and IL‑31 targeting biotech firms.
Limited to US‑listed biotech investors.
Modest; primarily relevant to specialty pharma investors.
Counterpoint
Phase 1b data are early; efficacy in larger Phase 2 trials remains uncertain, risk of setbacks.
Key entities
- companyAttovia Therapeutics, Inc.
Developer of ATTO‑1310, an anti‑IL‑31 therapy.

